Endothelial dysfunction in endocrine disease

Trends in Endocrinology and Metabolism

Volumn 12, Issue 6, 2001, Pages 257-265

  Abdu, Tarig A M ^a   Elhadd, Tarik ^a   Pfeifer, Marija ^b   Clayton, Richard N ^a  

^a KEELE UNIVERSITY   (United Kingdom)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

ACROMEGALY; CARDIOVASCULAR DISEASE; ENDOCRINE DISEASE; FEMALE; HUMAN; HYPERPARATHYROIDISM; HYPOPITUITARISM; INSULIN RESISTANCE; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; REVIEW; THYROID DISEASE; VASCULAR ENDOTHELIUM;

ACROMEGALY; CARDIOVASCULAR DISEASES; ENDOCRINE SYSTEM DISEASES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERPARATHYROIDISM; HYPOPITUITARISM; INSULIN RESISTANCE; OBESITY; POLYCYSTIC OVARY SYNDROME; THYROID DISEASES;

EID: 0035430442     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(01)00425-8     Document Type: Review

References (108)

1. Tribe, R.M. and Poston, L. (1996) Oxidative stress and lipid in diabetes: a role in endothelium vasodilator dysfunction. Vasc. Med. 1 , 195-206
2. Radomski, M.W. and Salas, E. (1995) Nitric oxide - biological mediator, modulator and factor of injury: its role in the pathogenesis of atherosclerosis. Atheroselerosis 118 (Suppl), 569-580
3. Ross, R. (1999) Atherosclerosis: an inflammatory disease. New Engl. J. Med. 340, 115-126
4. Anderson, T.J. (1999) Assessment and treatment of endothelial dysfunction in humans. J. Am. Coll. Cardiol. 34, 631-638
5. Blann, A.D. and Lip, G.Y. (1998) Endothelial integrity, soluble adhesion molecules and platelet markers in type 1 diabetes mellitus. Diabetic Med 15, 634-642
6. Consente, F. and Luscher, T.F. (1998) Endothelial dysfunction in diabetes mellitus. J. Cardiovasc. Pharmacol 32 (Suppl. 3) S54-S61
7. Anderson, T.J. et al. (1995) Close relation of endothelial function in the human coronary and peripheral circulations. J. Am. Coll. Cardiol. 26, 1235-1241
8. Calles-Escandon, J. and Cipolla, M. (2001) Diabetes and endothelial dysfunction: a clinical perspective. Endocr. Rev. 22, 36-52
9. Kirpichnikov, D. and Sowers, J.R. (2001) Diabetes mellitus and diabetes-associated vascular disease. Trends Endocrinol. Metab. 12, 225-230
10. Elhadd, T.A. et al. (1999) Abnormal markers of endothelial cell activation and oxidative stress in children, adolescents and young adults with Type-1 diabetes mellitus in the absence of clinical vascular disease. Diabetes Metabol. Res. Rev. 15, 405-411
11. Elhadd, T.A. et al. (1996) High levels of cell adhesion molecules, E-selection and ICAM-1 in diabetic patients with and without asymptomatic peripheral arterial disease. Diabetes Med. 13 (Suppl. 7) S19
12. Laakso, M. et al. (1990) Decreased effect of insulin to stimulate skeletal muscle blood flow in obese men. J. Clin. Invest. 85, 1844-1852
13. Baron, A.D. and Brechtel, G. (1993) Insulin differentially regulates systemic and skeletal muscular vascular resistance. Am. J. Physiol. 265, E61-E67
14. Baron, A.D. et al. (1993) Skeletal muscle blood flow: a possible link between insulin resistance and blood pressure. Hypertension 21, 129-135
15. Baron, A.D. et al. (1994) Skeletal muscle blood flow independently modulates insulin-mediated glucose uptake. Am. J. Physiol. 266, E248-E253
16. Scherrer, U. et al. (1994) Nitric oxide release accounts for insulin's vascular effects in humans. J. Clin. Invest. 94, 2511-2515
17. Aljada, A. et al. (2000) Insulin inhibits the expression of intercellular adhesion molecule-1 by human aortic endothelial cells through stimulation of nitric oxide. J. Clin. Endocrinol. Metab. 85, 2572-2575
18. Arcaro, G. et al. (1999) Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity. Int. J. Obes. 23, 936-942
19. Steinberg, H.O. et al. (1996) Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J. Clin. Invest. 11, 2601-2610
20. Dunaif, A. (1997) Insulin resistance in PCOS. Endocr. Rev. 18, 774-798
21. Wild, S. et al. (2000) Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study Clin. Endocrinol. 52, 595-600
22. Pinkney J.H. et al. (1997) Endothelial dysfunction: cause of insulin resistance syndrome. Diabetes 46 (Suppl. 2), S9-S13
23. Vane, J.R. et al. (1990) Regulatory functions of vascular endothelium. New Engl. J. Med. 323, 7-36
24. Stehouwer, C.D.A. et al. (1995) Endothelial dysfunction precedes development of microalbuminuria in IDDM. Diabetes 44, 561-564
25. Stehouwer, C.D.A. et al. (1992) Urinary microalbumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 340, 319-323
26. Lillioja, S. et al. (1987) Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man. J. Clin. Invest. 80, 415-424
27. Lithell, H. et al. (1981) Body weight skeletal muscle morphology and enzyme activities in relation to fasting serum insulin concentration and glucose tolerance in 48-year-old men. Diabetes 30, 19-25
28. Jansson, P.E. et al. (1993) Measurement by microdialysis of the insulin concentration in subcutaneous interstitial fluid. Diabetes 42, 1469-1473
29. Castillo, C. (1994) Interstitial insulin concentration determines glucose uptake rates but not insulin resistance in lean and obese men. J. Clin. Invest. 93, 10-16
30. Miles, F.D.G. et al. (1995) Kinetics of insulin action in vivo: identification of rate limiting steps. Diabetes 44, 947-953
31. Mather, K.J. et al. (2000) Normal endothelial function despite insulin resistance in healthy women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 85, 1851-1856
32. Jilma, B. et al. (2000) Effects of hyperinsulinaemia on plasma levels of circulating adhesion molecules. J. Clin. Endocrinol. Metab. 85, 1748-1751
33. Yudkin, J.S. et al. (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue. Arterioscler. Thromb. Vasc. Biol. 19, 972-978
34. Ridker, P.M. et al. (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New Engl. J. Med. 342, 836-843
35. Winkler, G. et al. (1999) Elevated Serum TNF-alpha level as a link between endothelial dysfunction and insulin resistance in normotensive obese patients. Diab. Med. 16, 207-211
36. Bakker, S.J. et al. (2000) Cytosolic triglycerides and oxidative stress in central obesity: the missing link between excessive atherosclesosis, endothelial dysfunction, and beta-cell failure. Atherosclerosis 148, 17-21
37. Ciccone, M. et al. (1992) Oxidative stress is an early marker of endothelial dysfunction? Clin. Hemorheol. Microcirc. 21, 341-342
38. Watts, G.F. et al. (2000) Effects of diet and serotonin agonist on hepatic apolipoprotein B-100 secretion and endothelial function in obese men. Q. J. Med. 93, 153-161
39. Rajkhowa, M. and Clayton, R.N. (1995) Polycystic ovary syndrome. Curr. Opin. Obs. Gynaecol. 5, 191-201
40. Franks, S. (1995) Polycystic ovary syndrome. New Engl. J. Med. 333, 853-857
41. Paradisi, G. et al. (2001) Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 103, 1410-1415
42. Worboys, S. et al. (2001) Evidence that parental testosterone therapy may improve endothelium-dependent and -independent vasodilation in postmenopausal women already receiving estrogen. J. Clin. Endocrinol. Metab. 86, 158-161
43. Bates, A.S. et al. (1993) An audit of outcome in the treatment of acromegaly. Q. J. Med. 86, 293-299
44. Orme, S.M. et al. (1998) Mortality and cancer incidence in acromegaly: a retrospective cohort study. J. Clin. Endocrinol. Metab. 83, 2730-2734
45. Chanson, P et al. (1998) Decreased regional blood flow in patients with acromegaly. Clin. Endocrinol. 49, 725-731
46. Dullart, R.P. et al. (1992) Effect of somatostatin analogue Octreotide on renal haemodynamics and albuminuria in acromegalic patients. Eur. J. Clin. Invest. 22, 494-502
47. Avagnina, P. et al. (1996) Assessment of functional liver mass and plasma flow in acromegaly before and after long term treatment with octreotide. Metabol. Clin. Exp. 45, 109-113
48. Evans, L.M. and Davies, J.S. (1998) Heterogeneous haemodynamics in acromegaly: evidence of endothelial dysfunction? Clin. Endocrinol. 49, 711-712
49. Maison, P. et al. (2000) Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstruction. Clin. Endocrinol. 53, 445-451
50. Beshyah, S.A. and Johnston, D.G. (1999) Cardiovascular disease and risk factors in adults with hypopituitarism. Clin. Endocrinol. 50, 1-15
51. Rosen, T. and Bengtsson, B-A. (1990) Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336, 285-288
52. Markussis, V. et al. (1992) Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet 340, 1188-1192
53. Capaldo, B. et al. (1997) Increased arterial intima-media thickness in childhood onset growth hormone deficiency. J. Clin. Endocrinol. Metab. 82, 1378-1381
54. Pfeifer, M. et al. (1999) Growth hormone treatment reverses early atherosclerotic changes in GH-deficient adults. J. Clin. Endocrinol. Metab. 84, 453-457
55. Borson-Chazot, F. et al. (1999) Decrease in carotid IMT after one year growth hormone (GH) treatment in adults with GH deficiency. J. Clin. Endocrinol. Metab. 84, 1329-1333
56. Evans, L.M. et al. (1999) Endothelial dysfunction in hypopituitary adults with GH deficiency. Clin. Endocrinol. 50, 457-464
57. Christ, E.R. et al. (1999) Growth hormone replacement therapy in adults with growth hormone deficiency improves vascular reactivity. Clin. Endocrinol. 51, 21-25
58. Evans, L.M. et al. (2000) The effect of growth hormone replacement on endothelial function and oxidative stress in adult growth hormone deficiency Eur. J. Endocrinol. 142, 254-262
59. Capaldo, B. et al. (2001) Abnormal vascular reactivity in growth hormone deficiency. Circulation 103, 520-526
60. Kvasnicka, J. et al. (2000) Increase of adhesion molecules, fibrinogen, type-1 plasminogen activator inhibitor and orosomucoid in growth hormone (GH) deficient adults and their modulation by recombinant human GH replacement. Clin. Endocrinol. 52, 543-548
61. Elhadd, T.A. et al. Relationship between biochemical and biophysical markers of endothelial dysfunction in patients with growth hormone deficiency: the missing link between hypopituitarism and reduced life expectancy? J. Clin. Endocrinol. Metabol. (in press)
62. Sesmilo, G. et al. (2000) Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomised controlled clinical trial. Ann. Intern. Med. 133, 111-122
63. Johansson, J-O. et al. (1994) High fibrinogen and plasminogen activator inhibitor activity in growth hormone deficient adults. Arterioscler. Thromb. 14, 434-437
64. Johansson, J-O. et al. (1996) Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone deficient adults. Thromb. Haemost. 76, 422-428
65. Serri, O. et al. (1999) Alteration of monocyte function in patients with growth hormone deficiency. Effect of substitutive GH therapy. J. Clin. Endocrinol. Metabol. 84, 58-63
66. Massaeli, H. and Pierce, G.N. (1995) Involvement of lipoproteins, free radicals and calcium in cardiovascular disease processes. Cardiovasc. Res. 29, 597-603
67. Franklyn, J. (1999) Thyroid disease and its treatment: short and long-term consequences. J. R. Coll. Phys. London 33, 564-567
68. Li, Y. et al. (1998) Impaired release of tissue plasminogen activator from the endothelium in Graves disease - indicator of endothelial dysfunction and reduced fibrinolytic activity. Eur. J. Clin. Invest. 28, 1050-1054
69. Rogers, J.S. (1982) Factor VIII activity and thyroid function. Ann. Inter. Med. 97, 713-716
70. Liu, L. et al. (1993) Elevated plasma level of vWFAg in hyperthyroidism are mediated through beta adrenergic receptors. Endocrine Res. 19, 123-133
71. Lekakis, J. et al. (1997) Flow-mediated endothelium-dependent vasodilatation is impaired in subjects with hypothyroidism, borderline hypothyroidism, and high normal serum thyrotropin (TSH) values. Thyroid 7, 411-414
72. Vanderpump, M.P. et al. (1996) The development of ischemic heart disease in relation to autoimmune thyroid disease in a 20-year follow-up study of an English community. Thyroid 6, 155-160
73. Hedbach, G. et al. (1991) The influence of surgery on the risk of death in patients with primary hyperparathyroidism. World J. Surg. 15, 399-407
74. Palmer, M. et al. (1987) Survival and renal function in untreated hypercalcaemia: population-bases cohort study with 14 years of follow up. Lancet 1, 59-62
75. Soreide, J.A. et al. (1997) Survival after surgical treatment for primary hyperparathyroidism. Surgery 122, 1117-1123
76. Ljunghall, S. et al. (1989) Primary hyperparathyroidism: the surgically cured patient. In Clinical Disorders of Bone and Mineral Metabolism (Kleerekoper, M. and Krane, S.M., eds), pp. 353-358, Mary Ann Liebert
77. Kosch, M. et al. (2000) Studies on flow-mediated vasodilation and intima-media thickness of the brachial artery in patients with primary hyperparathyroidism. Am. J. Hypertens. 13, 759-764
78. Schleiffer, R. et al. (1995) Endothelium is a target organ of parathyroid secretions in genetic hypertensive rats. Horm. Metab. Res. 27, 16-18
79. Jiang, B. et al. (1998) Expression of parathyroid hormone/parathyroid hormonerelated protein receptor in vascular endothelial cells. J. Cardiovas. Pharmacol. 31 (Suppl. 1), 142-144
80. Nilsson, I.L. et al. (1999) Endothelial vasodilatory dysfunction in primary hyperparathyroidism is reversed after parathyroidectomy Surgery 126, 1049-1055
81. Gordon, T. et al. (1978) Menopause and coronary heart disease: the Framingham study. Ann. Intern. Med. 89, 157-161
82. La, V.C. (1992) Sex hormones and cardiovascular risk. Hum. Reprod. 7, 162-167
83. Stampfer, M.J. et al. (1991) Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow up from the Nurses Health Study. New Engl. J. Med. 325, 756-762
84. Bracamonte, M.P and Miller, V.A. (2001) Estrogens: arterial protection versus increased risk of venous thrombosis. Trends Endocrinol. Metab. 12, 204-209
85. Gilligan, D.M. et al. (1994) Acute vascular effects of oestrogen in postmenopausal women. Circulation 90, 786-791
86. Gerhard, M. et al. (1998) Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation 98, 1158-1163
87. Collins, P et al. (1995) 17 beta Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 92, 24-30
88. Hashimoto, M. et al. (1995) Modulation of endothelium-dependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle. Circulation 92, 3431-3435
89. Arora, S. et al. (1998) Estrogen improves endothelial function. J. Vasc. Surg. 27, 1141-1146
90. Lieberman, E.H. et al. (1994) Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann. Inter. Med. 121, 936-941
91. Bush, D.E. et al. (1998) Estrogen replacement reverses endothelial dysfunction in postmenopausal women. Am. J. Med. 104, 552-558
92. Kennedy, G. et al. (1999) Elevated levels of E-selectin in postmenopausal females are decreased by hormone replacement therapy to levels observed in pre-menopausal females. Thromb. Haemost. 82, 1433-1436
93. Tagawa, H. et al. (1997) Short-term oestrogen augments both nitric oxide-mediated and nonnitric oxide-mediated endothelium-dependent forearm vasodilation in postmenopausal women. J. Cardiovasc. Pharmacol. 30, 481-488
94. Simoncini, T. and Genazzani, A.R. (2000) Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase. J. Clin. Endocrinol. Metab. 85, 2966-2969
95. Hayashi, T. et al. (1992) Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: the implication for atherosclerosis. Proc. Natl. Acad. Sci. U. S. A. 89, 11259-11263
96. Wellman, G.C. (1996) A proposed mechanism for the cardio-protective effect of oestrogen in women: enhanced endothelial nitric oxide release decreases coronary artery reactivity. Clin. Exp. Pharmacol. Physiol. 23, 260-266
97. Bush, T.L. et al. (1988) Cholesterol, lipoproteins and coronary heart disease. Clin. Chem. 34, B60-B70
98. Barrett-Conner, E. and Bush, T.L. (1991) Estrogen and coronary heart disease in women. JAMA 265, 1861-1867
99. Guzic-Salobir, B. et al. (2000) Hormone replacement therapy reduces expression of cell adhesion molecules in healthy postmenopausal women. Atherosclerosis 151 (Suppl. 1), 243-244
100. Hornig, B. et al. (1997) Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 95, 1115-1118
101. Gibbons, G.H. (1997) Vasculoprotective and cardioprotective mechanisms of angiotensin-converting enzyme inhibition: the homeostatic balance between angiotensin II and nitric oxide. Clin. Cardiol. 20 (Suppl. 2), II18-II25
102. Mancini, G.B. et al. (1996) Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 94, 258-265
103. O'Driscoll, G. (1997) Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 95, 1126-1131
104. Laufs, U. et al. (1998) Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97, 1129-1135
105. Levine, G.N. et al. (1996) Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 93, 1107-1113
106. Ting, H.H. et al. (1996) Vitamin C improves endothelium-dependent vasodilatation in patients with non-insulin-dependent diabetes mellitus. J. Clin. Invest. 97, 22-28
107. Solzbach, U. et al. (1997) Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. Circulation 96, 1513-1519
108. Verhaar, M.C. et al. (1998) 5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation 97, 237-241